Rob Volansky is a staff writer for HEMONC TODAY, a publication associated with Healio. Rob covers a wide range of topics in the field of hematology and oncology, including the latest research, treatment advances, and clinical trials. His articles provide valuable insights and updates for healthcare professionals and researchers in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Rob's coverage predominantly focuses on healthcare and pharmaceuticals, particularly in the field of rheumatology and autoimmune diseases. He relies heavily on data citations, indicating a preference for evidence-based information.
Since Rob covers a niche area within the medical field, he is likely to be interested in pitches that provide new research findings or expert insights related to rheumatology, autoimmune diseases, COVID-19 impact on these conditions, vaccines' effect on patients with such illnesses, and developments in relevant medications.
Given his high reliance on data citations, sources with access to cutting-edge research or clinical trial results would have significant appeal. Expert commentary from professionals directly involved in treating these conditions could also capture his interest.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Rob Volansky, Shenaz Bagha
SCOTTSDALE, Ariz. — Understanding the relationship between mental and physical distress is essential to breaking the cycle of chronic pain, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
By: Rob Volansky
SCOTTSDALE, Ariz. — Understanding the science of pain can help rheumatologists better manage fibromyalgia and other chronic conditions, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium. “Many rheumatologists just don’t want to deal with pain,” Philip J. Mease, MD, of the Swedish Medical Center and the University of Washington,
By: Rob Volansky, Shenaz Bagha
Despite the placebo effect's long history in medicine — not to mention the critical role placebo plays in randomized trials — the mechanism driving it remains poorly understood.
By: Rob Volansky, Shenaz Bagha
A recent legal battle over copay assistance programs for biologic medications, and whether they must count toward insurance deductibles, have resulted in a positive outcome for patients, according to the American College of Rheumatology.
By: Rob Volansky, Shenaz Bagha
A recent NIH study of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome suggests that the condition is a “distinct entity,” with somatic and cognitive issues that are centrally mediated.
The common consensus for some time has been that the prevalence of autoimmunity and autoimmune diseases has been on the rise.
By: Rob Volansky
Compared with the general U.S. population, Navajo Nation in Arizona, New Mexico and Utah has five times the prevalence of rheumatoid arthritis.
By: Rob Volansky, Heather Biele
The age of biosimilars has come for gastroenterology. This includes interchangeable products, three of which are now on the market. How this will impact patient care in the near and distant future is the subject of much speculation.
By: Rob Volansky, Shenaz Bagha
This year's Congress of Clinical Rheumatology-East will celebrate the annual meeting's 40 anniversary with banquets, record in-person attendance and a host of new presenters.
By: Rob Volansky
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.
(833) 317-6278 
